Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-03-05

Clinical Trial Update: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for ONTAK (denileukin diftitox) in Cutaneous T-Cell Lymphoma; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ONTAK (denileukin diftitox)

Snippet

Sponsor: Eisai Inc. | Conditions: Lymphoma, T-Cell, Cutaneous | Phase 4 | Status: COMPLETED